SEC Filing Summary: Galena Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Galena Biopharma, Inc. on March 28, 2017, reporting an event that occurred on March 24, 2017. The filing addresses a regulatory notice regarding the company's stock listing status on the NASDAQ Capital Market. Note: The request metadata referenced "SELLAS Life Sciences Group, Inc.," but the provided filing text explicitly identifies the registrant as Galena Biopharma, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory notice:
- Stock Price: The closing bid price for the Company's common stock was below $1.00 per share for the previous 30 consecutive business days.
Material Changes
The material change reported is the receipt of a formal notice from The NASDAQ Stock Market stating the Company is not in compliance with NASDAQ Listing Rule 5550(a)(2) due to the sustained low bid price. This notice initiates a compliance period but has no immediate effect on the listing or trading of the stock.
Outlook, Risks, and Contingencies
Compliance Timeline: The Company has an initial grace period of 180 calendar days (until September 20, 2017) to regain compliance.
Compliance Requirements: To regain compliance, the bid price must close at $1.00 or more for a minimum of 10 consecutive business days.
Contingencies and Risks:
- If the initial grace period expires without compliance, a second 180-day grace period may be granted if the Company has at least $1,000,000 in market value of shares held by non-affiliates and meets other initial listing requirements.
- If the deficiency cannot be cured during the second period, the Company expects to receive a delisting notification.
- The Company may request a hearing before the NASDAQ Listing Qualifications Panel to present a plan to regain compliance, which would stay the delisting process pending the Panel's decision.
- Further appeals to the NASDAQ Listing and Hearing Review Council are possible but will not stay the delisting process.
Key Facts for Investor Verification
- Verify the current closing bid price of Galena Biopharma, Inc. stock to assess progress toward the $1.00 threshold.
- Confirm the Company's market value of shares held by non-affiliates to determine eligibility for a second grace period if needed.
- Monitor for any subsequent filings regarding a reverse stock split or other corporate actions intended to cure the listing deficiency.
- Check for any hearing requests filed with the NASDAQ Listing Qualifications Panel if the initial 180-day period expires without compliance.